OBJECTIVES: The study evaluated recent data related to real impact measurement of HPV prevention or cervical oncologic diseases related to HPV infection available from publications in the EU member states. The main idea was to find out whether there is any prerequisite to evaluate the effectiveness of the preventive HPV vaccination based on the existing data and standard approaches within the EU in the future in an observational study. The second goal was to define these prerequisites in order to use them for “good practice”. METHODS: The systematic review of PUBMED, EMBASE and CENTRAL extended to official websites of public health institutions officially published data was used. The goal was to find all papers on HPV/cervical cancer epidemiology, screening, and prevention published in years 2009- 2011, related to EU member states. Only studies related to countries from the European Union were taken into account. All relevant data were extracted and compared. Population size was derived from Eurostat. Based on this data we created the principles for evaluation of HPV screening and monitoring of quality indicators. RESULTS: Out of 27 EU countries, only 2 countries (Denmark and United Kingdom) received the highest value for screening and monitoring of quality indicators. The data retrieved from their standard approaches in screening could be a baseline for the comparison between the modelling of effectiveness data and real data. New data required were defined as the condition to formulate an optimal design for valued surveillance of the effectiveness of HPV vaccination in general population. CONCLUSIONS: Some harmonization of screening and monitoring of active surveillance would be necessary within the EU member states in order to increase the reliability of real world data effectiveness. The proposal for defined criteria is needed for valuable evaluation the real effectiveness of HPV vaccination in general population in prospective studies.